Jonathan D. Rosen, our former Chief Executive Officer and Chairman, had more than 20 years of experience as an executive and business leader, serving as Founder, CEO, and Chairman of Entaire Global Companies, Inc. prior to its sale to Synovus Bank in 2016. Mr. Rosen subsequently served as Divisional CEO, Specialty Finance at Synovus Bank. He was also the managing trustee of the Jonathan D. Rosen Family Foundation, Inc. and a trustee of the Georgia Council on Economic Education. He was the primary inventor on 3 patents issued by the USPTO, including the development of a system for managing the total risk exposure for a portfolio of loans, a method for compensating an employee, and a financing and securitizing structure for a portfolio of loans. Mr. Rosen held a Bachelor of Science degree from the Wharton School at the University of Pennsylvania and attended Emory University School of Law.

Mr. Fennell currently serves as Corporate Development Strategist for F3 Platform Biologics and has provided services for the Company in various capacities since 2021. Mr. Fennell brings more than 8 years of financial services and advisory experience, primarily focused on early stage healthcare companies. Prior to joining F3, Mr. Fennell was a healthcare focused investment banker at Citigroup, Inc. and at Oppenheimer & Company before that. He began his career at Valuation Research Corporation, where he provided business valuations and corporate services to private equity clients. He holds a BS in Financial Analysis from the University at Albany within its School of Business Honors program. 

Dr. David Grdina, co-chair of our SAB, is an expert in the field of radiation biophysics and heads the Grdina Laboratory at the University of Chicago. He completed his doctoral training at the University of Kansas in 1971 and has been working with the University of Chicago since 1991. Starting in 1983 at the Argonne National Laboratory, Dr. Grdina began work on developing amifostine as an anti-mutagenic and anti-carcinogenic drug. Dr. Grdina first published his findings on amifostine in 1991 and has since published a total of 83 peer-reviewed articles on the subject. In 1996, his laboratory was moved to the University of Chicago, where work continued defining and examining amifostine’s use as a genomic protector and inhibitor of genomic instability culminating. This culminated in six U.S. Patents (US # 5488042; 5567686; 5869338; 589191.46; 6984619; and 9877976) with the most recent being issued in 2018: US 9,877,976 “Methods and Compositions for Protection of Cells and Tissues from Computed Tomography Radiation.”

Dr. David I. Rosenthal is a Professor of Radiation Oncology and Head & Neck Surgery at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Rosenthal is a sub-specialist expert in head and neck radiation oncology and serves as Chief of the MD Anderson Head & Neck Radiation Oncology Service that represents greater than a century of Head & Neck physician cancer expertise by nine radiation oncology physicians, and a specialized team of radiotherapy physician assistants, nurses, physicists, therapists, and dosimetrists. Dr. Rosenthal and his team treat all types of Head & Neck and skin cancers, and work closely with colleagues from other related specialties to derive personalized treatment plans for each individual patient. He is a Fellow of the American College of Radiology (FACR), the American Society for Radiation Oncology (FASTRO), and the American Head & Neck Society (AHNS). Dr. Rosenthal focuses on developing new methods to improve survival and functional outcomes, and techniques to reduce side-effects and toxicities from Head & Neck cancer treatment. These include proton therapy, intensity-modulated radiation therapy, volumetric-modulated arc therapy, stereotactic body radiation therapy, drug development, immunotherapy, acute and late toxicity evaluation (including mucositis, dermatitis, dysphagia, and xerostomia), their management, prevention, patient reported outcomes, and quality and safety research. Dr. Rosenthal serves as principal investigator for numerous national cooperative group and institutional clinical trials; has over 200 related peer-reviewed publications and is co-editor of a textbook: Head and Neck Cancers: Evidence-Based Treatment. He is a 1984 graduate of the University of Miami (FL) School of Medicine.

Dr. David Brenner studied radiation physics at the Medical College of St. Bartholomew’s Hospital, University of London, and obtained a PhD from the University of Surrey Physics Department. Dr. Brenner currently directs the Center for Radiological Research at Columbia University Medical Center in New York City. The Center, now in its 102nd year, was founded by a student of Marie Curie with the goal of exploiting radiation to improve medical care. Dr. Brenner has been published on the topic of low dose radiation and has designed new “patient friendly” approaches for prostate cancer radiation therapy that are now in common use worldwide, and he is currently very excited about the prospects of beating pancreatic cancer with new types of radiation. Over the past 6 years, he has also been working towards a safe way to kill drug-resistant bacteria such as MRSA, as well as airborne viruses such as influenza, using a unique type of ultraviolet light.

Dr. Winston Marshall is a board-certified cardiologist in the areas of cardiovascular disease and interventional cardiology. Dr. Marshall received his medical degree from the University of Southwestern Texas Medical School and completed his Residency in Internal Medicine and a Fellowship in Cardiovascular Disease at Baylor University Medical Center. Dr. Marshall is currently affiliated with Baylor Scott & White, The Heart Hospital — Plano. He has been in practice for over twenty years and his areas of expertise include invasive and noninvasive heart evaluations and peripheral and coronary interventions.

Dr. Archie Bleyer is renowned for his pediatric oncology medical contributions. A University of Rochester School of Medicine and Dentistry graduate, Dr. Bleyer currently serves as the Medical Director, Clinical Research and Director, DEFEAT Cancer, St. Charles Regional Cancer Center, the Chair of the Institutional Research Board, Cascade Healthcare Community, the Director of Aflac/Cure Search Adolescent and Young Adult Cancer Research and was a founding member of the LiveStrong Young Adult Alliance. He chaired the Children’s Cancer Group for 10 years, then the world’s largest pediatric cancer research organization, as well as the Department and Division of Pediatrics at the University of Texas MD Anderson Cancer Center and the Community Oncology in the Department and Division of Medicine at the MD Anderson Cancer Center. Dr. Bleyer was the American Cancer Society Professor of Clinical Oncology and in charge of the cancer curriculum at the University of Washington School of Medicine. During the past three decades, Dr. Bleyer was awarded research grants totaling more than $75 million as a principal investigator from the National Institutes of Health, the American Cancer Society, and the Leukemia Society of America. His research has been published in more than 300 peer-reviewed articles, chapters, and books. His current personal clinical research is dedicated to adolescents and young adult (AYA) oncology.

Jeffrey S. Murley, PhD is a Molecular Radiation Biologist and Research Laboratory Manager at the Department of Radiation Oncology and Northwestern University. Previously, he was a Research Associate and Associate Professor in the Department of Radiation and Cellular Oncology at The University of Chicago. Dr. Murley completed his masters in biological sciences and doctoral studies at Northern Illinois University. His research focuses include adaptive responses induced by very low doses of ionizing radiation and the intracellular signaling pathways involved in these responses. Dr. Murley has spent over 18 years at the University of Chicago studying radiation and cellular oncology, much of that time working alongside our SAB co-chairman, Dr. Grdina. Dr. Murley has been peer reviewed and published at least 50 times and has presented as a lecturer and presenter at industry events nearly 90 times.

Dr. Richard Albertini is a Research Professor in the Department of Pathology at the University of Vermont. Dr. Albertini has been a professor in the pathology field for over 45 years. He has written at length on topics ranging from genotoxic carcinogens to biomonitoring and has been instrumental in innovating HPRT cell measurement to aid cancer detection. Dr. Albertini obtained his M.D. and Ph.D. from the University of Wisconsin — Madison.

Dr. Frush is the John Strohbehn Professor of Radiology, and an Associate Faculty Member, Medical Physics Graduate Program at Duke University Medical Center. Dr. Frush earned his undergraduate degree from the U.C. Davis, MD from Duke University School of Medicine, was a pediatric resident at U.C. San Francisco, completed a radiology residency at Duke Medical Center and a fellowship in pediatric radiology at Children’s Hospital in Cincinnati. Professional roles included more than 25 years on the Duke Medical Center faculty, with a subsequent nearly two-year appointment as a Professor of Radiology at Lucile Packard Children’s Hospital at Stanford. He returned to Duke in 2020. Dr. Frush’s research interests are predominantly involved with pediatric body computed tomography (CT), including technology assessment, techniques for pediatric CT examinations, assessment of image quality, radiation dosimetry, and radiation protection and risk communication in medical imaging. Other areas of investigation include CT applications in children and patient safety in radiology. Contributions to the advancement of medicine to date include more than 260 peer reviewed publications and 40 book chapters.

Dr. Koukourakis is a Professor of Radiation Oncology, and Head of the Department of Radiotherapy and Oncology, Medical School, Democritus University of Thrace. He graduated the Medical School of the University of Athens, Greece, specialized in Radiotherapy and Oncology at the Hellenic Cancer Institute, and in Clinical Oncology at the University of Paris VII, France. He obtained his PhD diploma at the University of Crete. He followed post-doctoral studies (British Council Fellowship) at the University of Oxford, ICRF Medical Oncology Unit, where he worked in early phase clinical studies on novel agents and in translational research projects related to angiogenesis and drug resistance. His clinical research interests focus on the combinations of chemotherapy and immunotherapy with radiation and on the clinical development of cytoprotective regimens. He organizes and supervises a large number of collaborative clinicopathological studies on the pathogenetic, prognostic and predictive role of hypoxia, tumor metabolism and immune response. He has authored or co-authored more than 370 articles in peer reviewed journals, with more than 15,000 citations and the H-index of his published work is above 65.

Dr. Stenoien is CEO of Houston Medical Imaging with 8 locations in the greater Houston area and the Rio Grande Valley. Dr. Stenoien has a vast knowledge of interventional and oncology experience with an interest in cross-sectional and nuclear imaging. Dr. Randall A. Stenoien attended Bjorkelangen Videregaaende Skole in Norway in 1978. He received a Bachelor’s degree from Trinity University in San Antonio in 1981 and graduated from the University of Texas Medical School in 1984. He completed his Diagnostic Radiology residency at UT Southwestern in Dallas in 1988. He worked for Southwest Radiology Association until 2002, and subsequently founded Innovative Radiology, PA. Dr. Stenoien is active on several charitable boards as well as the Harris County Medical Society.

Dr. James Dziadziola Jr. is an otolaryngologist in Kannapolis, North Carolina and is affiliated with multiple hospitals in the area, including Carolina Healthcare System University Medical Center and Carolinas Healthcare Northeast. He received his medical degree from Wayne State University School of Medicine in 1991 and has been in practice for more than 20 years. Dr. Dziadziola is one of 44 doctors at Carolina Healthcare System University Medical Center and one of 7 at Carolinas Healthcare Northeast who specialize in Otolaryngology (ENT). He is a fellow of and board certified by the American Board of Otolaryngology, Head and Neck Surgery and is a member of the American Medical Association, the North Carolina Medical Society, the Cabarrus County Medical Society, the Charlotte Ear, Nose, and Throat Society, and the American Academy of Otolaryngologic Allergy.

Mr. Viren Grover joined our Scientific Advisory Group in 2019, bringing a wealth of experience of more than 40 years in the Healthcare Industry. He worked with Abbott Laboratories for 30 years in various capacities, including managing Abbott’s European Hospital business based in Paris, Head of Pacific, Asia, and Africa Business Development based in Chicago, Head of Abbott’s Pharma, Diagnostics and Nutritional businesses based in Indonesia and Turkey. During his term, Abbott Indonesia received the prestigious Government recognition “Best Medium Sized Company” in the country. After his retirement from Abbott, he co-founded Pinnacle Biologics, served as Vice-Chairman and played a key role in the acquisition of amifostine (Ethyol) from MedImmune/AstraZeneca, including amifostine licensing agreements with the University of Chicago. Mr. Grover did his graduate studies in Economics at Carleton University, Ottawa, Canada and in International Business at New York University’s Stern School of Business

Dr. Ralph Boccia is the President and Medical Director of the Center for Cancer and Blood Disorders, in Bethesda, Maryland. Dr. Boccia also holds positions as Clinical Associate Professor of Medicine at Georgetown University, Chief Medical Officer of the International Oncology Network and a member of the Advisory Panel for the American Oncology Network, while serving as the Chair of its Research Committee. He completed his medical residency in internal medicine and fellowship training in hematology, oncology, and bone marrow transplantation under a combined UCLA-VA fellowship program in Los Angeles, CA. Dr. Boccia also completed a fellowship in medical oncology and laboratory research at the National Cancer Institute in Bethesda, Maryland. Dr. Boccia’s publication credits include more than 180 articles, abstracts and posters, reporting research results from major clinical trials in several prestigious journals including the New England Journal of Medicine and the Journal of Clinical Oncology. Dr. Boccia serves on the editorial boards for the Journal of Hematology and Oncology, Community Oncology, Oncology and Biotechnology News and Targeted Therapies News.

F3 has a worldwide, exclusive license to amifostine-related intellectual property developed at the University of Chicago by the co-chair of our Scientific Advisory Board (“SAB”), Dr. David Grdina. Dr. Grdina has focused his professional research at the University of Chicago on developing new strategies to prevent therapy-induced secondary cancers in patients having a good prognosis and relatively long-life expectancy following treatment. Dr. Grdina has spent almost four decades focusing his research primarily on amifostine and its treatment benefits as a cytoprotectant. During that time, Dr. Grdina has conducted over 70 clinical and research trials focusing on the efficacy of amifostine as a radioprotectant against radiation-induced damage caused by CT scans.

Paste Aclairo Pharmaceutical Development Group Here

Daniel Courchesne has served as a director since October 4, 2019. Mr. Courchesne is currently President of Synovus’ Specialty Finance Division which includes the Asset Based Lending, Structured Lending and Global One divisions of Synovus Bank. He brings with him over 30 years of broad experience in the banking, investment and finance industry. Previously, Mr. Courchesne was President of Global One Financial Inc. & Senior Vice President of Entaire Global Companies, Inc. sold to Synovus in 2016. Mr. Courchesne’s areas of expertise include asset-backed/based lending, premium financing, securitization, financial derivatives, insurance and capital raising. Prior to joining Entaire Global Companies Inc., Mr. Courchesne was with Commerzbank (Dresdner Kleinwort Wasserstein), where he served as Managing Director of the firm’s North American Structured Credit Group. Prior to Commerzbank, Mr. Courchesne held several management and trading roles within the Royal Bank of Canada (RBC) including management of the Credit Arbitrage group. Mr. Courchesne earned his B.B.A in Finance from the University of Sherbrooke in 1987.

Drs. Machielse has served as the Chairman of Polyneuron Pharmaceuticals AG since 2019 and has been a director at Complexa since 2018. Drs. Machielse has also previously been a director at Vtesse, Inc. (until its acquisition by Sucampo), Xencor and TetraGenetics. Drs. Machielse previously served as Chief Executive Officer, and President at Vtesse, Inc (until its acquisition by Sucampo), Chief Operating Officer and Executive Vice President of Omthera Pharmaceuticals, Inc since 2010 (until its acquisition by Astra Zeneca) and as an Executive Vice President of Operations at MedImmune Inc. (Acquired by Astra Zeneca). Throughout his tenure at the various companies, Drs. Machielse was an important contributor to the successful development and launch of the first H1N1 vaccine available to the US public, the approval of Flumist, the approval of Epanova and the development of treatments for rare neurological diseases. Drs. Machielse served as a Vice President of Quality Control and Quality Assurance for Xoma Corporation of Berkeley, CA. Drs. Machielse also spent several years in various manufacturing and quality positions at Centocor BV in the Netherlands. Drs. Machielse holds a Bachelor of Science degree in Medical Biology and a Master of Science degree in Biochemistry from the University of Utrecht, The Netherlands.

Linda Peters brings over 30 years of global healthcare regulatory, quality and compliance leadership experience in biopharmaceuticals, vaccines and medical. In October 2021, Ms. Peters joined the board of directors for SunMed Medical and has also served on the board of directors for the Medical Device Innovation Forum (MDIC), Healthcare Institute of New Jersey (HINJ), and Sequoia Pharmaceuticals. Since 2019, Ms. Peters has been the Vice President at Google Health, where she was hired as part of the initial senior leadership team to enable the start-up of Google’s health business and to set the vision and strategy for a new, strategic health initiative, in both regulated medical devices and consumer health, chartered with business transformation to scale and accelerating Google’s growth in AI and Machine Learning in health. Prior to joining Google, she was EVP and Chief Regulatory Officer for Becton Dickson (BD), from 2017 to 2019, where she oversaw all global regulatory affairs and government affairs and public policy for a Fortune 200 company and the was a member of the executive team that led the acquisition and integration of CR Bard Medical for $24 billion.

Ms. Peters has been in roles of increasing levels responsibility as Senior Vice President for MedImmune (now AstraZeneca), from 2005 to 2010, and Vice President for Baxter Healthcare, from 2010 to 2015. She has led the strategic regulatory initiatives to successfully bring numerous biopharmaceutical, vaccine, and medical device products to market globally. She was a major contributor in helping to design the regulatory roadmap for software as a medical device (SaMD) as well as being a major contributor to the successful development, regulatory approval and launch of the first H1N1 vaccine in the US. She has led numerous negotiations with senior regulatory healthcare bodies, including the FDA, MHRA, EMA, Japan PMDA, China NMPA, Brazil ANVISA and India CDSCO. Ms. Peters holds a Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University as well as Master of Science and Bachelor of Science degrees in Animal Science from Southern Illinois University at Carbondale.

Mr. Peskoff has more than 25 years of experience maximizing value and guiding organizational growth for companies as an executive officer, entrepreneur, senior investment banker, venture capitalist and individual investor. He has advised on more than $30 billion in merger and acquisition assignments and has raised over $15 billion in public and private capital. Currently, Mr. Peskoff is the Chief Strategy Officer at the law firm Pintas Mullins LLC. Previously, Mr. Peskoff was a founder and President of Breakout Capital Finance, which was recently sold to SecurCapital Corp. For more than 11 years prior, he was a Managing Director and group head of the financial services mergers and acquisitions group at FBR Capital Markets. Before joining FBR, he was a General Partner at NextPoint Partners, an early stage venture capital firm, and a Vice President in the technology group at Credit Suisse First Boston. Mr. Peskoff also spent eight years in investment banking at UBS Warburg and Friedman, Billings, Ramsey and Company, Inc. He holds a BS in Finance from the University of Southern California.